Markets:

Overview

News

Currencies

International

Treasuries

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

89.43 -3.55 (-3.82%)

Streaming Delayed Price Updated: 3:27 PM EDT, May 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Rhythm Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

3 Stocks to Buy the Dip Now ↗

May 20, 2022

You've heard the adage "buy the dip," but not all dips are made equal. There are several strategies for finding worthwhile discounted stocks.

Via InvestorPlace

Stocks That Hit 52-Week Lows On Thursday ↗

May 05, 2022

During Thursday, 351 stocks hit new 52-week lows.

Via Benzinga

Rhythm Pharmaceuticals: Q1 Earnings Insights ↗

May 03, 2022

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported its Q1 earnings results on Tuesday, May 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For March 1, 2022 ↗

March 01, 2022

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...

Via Benzinga

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗

May 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Rhythm Pharmaceuticals Q1 2022 Earnings Conference Call On May 3, 2022 At 08:30 AM ET ↗

April 27, 2022

Rhythm Pharmaceuticals (NASDAQ:RYTM) will host a conference call at 08:30 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Rhythm Pharmaceuticals (RYTM) Conference Call Follow...

Via Benzinga

51 Biggest Movers From Yesterday ↗

April 07, 2022

Gainers Advent Technologies Holdings, Inc. (NASDAQ: ADN) shares climbed 79.7% to close at $3.63 on Wednesday. Advent Technologies and Hyundai Motor Company entered into...

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

February 14, 2022

During Monday's session, 291 companies made new 52-week lows. Also check out this: Insiders Buying These 4 Penny Stocks Noteable 52-Week Lows And Highs: SAP (...

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

February 04, 2022

On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap...

Via Benzinga

Earnings Scheduled For May 3, 2022 ↗

May 03, 2022

Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.

Via Benzinga

Earnings Scheduled For November 2, 2021 ↗

November 02, 2021

Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

April 06, 2022

Gainers Sunshine Biopharma (NASDAQ:SBFM) shares rose 32.4% to $7.43 during Wednesday's regular session. Sunshine Biopharma's stock is trading at a volume of 46.8...

Via Benzinga

40 Stocks Moving In Wednesday's Mid-Day Session ↗

April 06, 2022

Gainers Advent Technologies Holdings, Inc. (NASDAQ: ADN) shares jumped 77.7% to $3.5950. Advent Technologies and Hyundai Motor Company entered into technology assessment, sales...

Via Benzinga

Rhythm Pharma Shares Fall After Modifications To Setmelanotide Trials In Rare Diseases of Obesity ↗

April 06, 2022

Rhythm Pharmaceuticals Inc (NASDAQ: RYTM)

Via Benzinga

Rhythm Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗

March 04, 2022

Benzinga Pro data, Rhythm Pharmaceuticals (NASDAQ:RYTM) reported Q4 sales of $1.82 million. Earnings fell to a loss of $42.87 million, resulting in a 22.1% decrease from last...

Via Benzinga

Rhythm Pharmaceuticals: Q4 Earnings Insights ↗

March 01, 2022

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported its Q4 earnings results on Tuesday, March 1, 2022 at 08:00 AM. Here's what investors need to know about the announcement....

Via Benzinga

Thinking About Buying Stock In Lucid Group, Rhythm Pharmaceuticals Or Kohl's? ↗

February 28, 2022

Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings b...

Via Benzinga

A Preview Of Rhythm Pharmaceuticals's Earnings ↗

February 28, 2022

Rhythm Pharmaceuticals (NASDAQ:RYTM) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement....

Via Benzinga

Why Rhythm Pharmaceuticals Shares Are Falling Today ↗

February 24, 2022

The FDA has extended the review period for Rhythm Pharmaceuticals Inc's (NASDAQ: RYTM) supplemental marketing application for Imcivree (setmelanotide) for...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

February 17, 2022

Gainers Rhythm Pharmaceuticals (NASDAQ:RYTM) stock increased by 16.4% to $7.72 during Thursday's regular session. The current volume of 639.5K shares is 152.7% of...

Via Benzinga

60 Biggest Movers From Yesterday ↗

February 18, 2022

Gainers Inspirato Incorporated (NASDAQ: ISPO) shares climbed 618.2% to close at $92.65 on Thursday, just a few days after the company completed its SPAC merger with Thayer...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 17, 2022 ↗

February 17, 2022

Upgrades HSBC upgraded the previous rating for Equinor ASA (NYSE:EQNR) from Hold to Buy. For the fourth quarter, Equinor had an EPS of $1.35, compared to year-ago quarter EPS of $...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

February 17, 2022

Gainers NeuroOne Medical Tech (NASDAQ:NMTC) shares moved upwards by 12.3% to $3.0 during Thursday's pre-market session. The company's market cap stands at $48.5...

Via Benzinga

Rhythm Pharma's Highlights Interim Setmelanotide Data In Long Term Genetic Disorder Trial ↗

February 16, 2022

Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) has announced interim data from its long-term extension study evaluating setmelanotide in patients with Bardet-Biedl...

Via Benzinga

Week In Review: Shanghai Regor To Discover Metabolic Therapies For Lilly In $1.55 Billion Deal ↗

December 11, 2021

Regor Therapeutics entered a $1.55 billion research pact with Eli & Lilly to discover therapies for metabolic disorders. Meanwhile, Beijing Avistone Pharma received a $200 million investment led by...

Via Talk Markets

Rhythm Pharma's Imcivree Wins UK Approval For Obesity, Hunger Control ↗

September 22, 2021

Britain's Medicines & Healthcare Products Regulatory Agency (MHRA) has approved Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) Imcivree (setmelanotide) for...

Via Benzinga

52 Weeks High And Low Article ↗

February 11, 2022

On Friday, 106 companies reached new 52-week lows. Things to Consider About Today's 52-Week Lows: Air Products & Chemicals (NYSE:APD) is the largest company...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021 ↗

December 08, 2021

Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 ↗

November 19, 2021

Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:

Via Benzinga

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology ↗

October 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.